[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperuricemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperuricemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,78,108,140,162,184,204,225,246,265,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644292","evaluation-of-the-effect-of-hyperuricemia-on-alveolar-bone-loss-100644292",false,"NCT07666126","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress","Inclusion Criteria:\n\n* Being between 18 and 65 years of age\n* Being systemically healthy or diagnosed with hyperuricemia\n* Having at least 20 natural teeth\n* Being periodontally healthy or diagnosed with periodontitis\n\nExclusion Criteria:\n\n* Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.\n* Smoking\n* Pregnancy or lactation\n* Having received periodontal treatment within the last 3-6 months\n* Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs\n* Presence of systemic diseases that may affect purine metabolism",true,"ALL","18 Years","65 Years",{"count":21,"type":22},80,"ESTIMATED","OBSERVATIONAL","Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.\n\nA total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.",[26,27,28],"Periodontal Diseases","Hyperuricemia","Oxidative Stress",[30,31,32,33,34],"periodontal disease","hyperuricemia","oxidative stress","alveolar bone loss","inflammation","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":22},"2026-06-10",{"date":43,"type":22},"2026-10-01",{"name":45,"class":46},"Recep Tayyip Erdogan University Training and Research Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100630965","chronic-kidney-disease-and-metabolic-disorders-in-the-elderly-100630965","NCT07494526","Chronic Kidney Disease and Metabolic Disorders in the Elderly","Research on the Prevention, Control, and Intelligent Management Decision-Making for Comorbidities of Chronic Kidney Disease and Metabolic Disorders in the Elderly","For Sub-cohort 1, the inclusion and exclusion criteria are as follows:\n\nInclusion Criteria:\n\n1. Baseline age ≥ 65 years.\n2. Availability of baseline data on serum creatinine and at least one urinary protein measurement.\n3. Urinary protein measurements include: UACR, UPCR, 24-hour urine protein quantification, and urine protein dipstick test.\n4. Baseline date requirement: Between January 1, 2010, and December 31, 2025.\n5. Follow-up requirement meeting at least one of the following: At least one serum creatinine measurement with an interval of ≥ 6 months after baseline. Occurrence of a primary endpoint event (new-onset CKD).\n\nExclusion Criteria:\n\nPresence of CKD at baseline, defined as: Glomerular filtration rate (eGFR) \\\u003C 60 ml\u002F(min·1.73m²) or positive urine protein; or the presence of an ICD-10 diagnostic code for CKD in medical records.\n\nFor Sub-cohort 2 (CKD Patients), the inclusion and exclusion criteria are as follows:\n\nInclusion Criteria:\n\n1. Baseline age ≥ 65 years.\n2. Meeting the diagnostic criteria for CKD: Glomerular filtration rate (eGFR) \\\u003C 60 ml\u002F(min·1.73m²) or urine protein (UACR ≥ 30 mg\u002Fg); or based on ICD-10 codes.\n3. Baseline date requirement: Between January 1, 2010, and December 31, 2025.\n4. Follow-up requirement meeting at least one of the following:\n\nOccurrence of a primary endpoint event (mortality, ESRD); At least one serum creatinine measurement with an interval of ≥ 6 months after baseline.\n\nExclusion Criteria:\n\n1. End-stage renal disease (ESRD) at baseline (eGFR \\\u003C 15 ml\u002F(min·1.73m²), or prior receipt of kidney transplant or dialysis), based on ICD codes).\n2. Diagnosis of acute kidney injury (AKI) within the preceding 3 months.\n3. New York Heart Association (NYHA) Class III or IV heart failure or occurrence of acute myocardial infarction within the preceding 6 months.\n4. Child-Pugh Class B or C liver cirrhosis.\n5. Malignant neoplasm.",{"count":56,"type":22},100000,"The goal of this observational study is to investigate the impact of metabolic comorbidities on outcomes in elderly Chinese adults, through two parallel sub-cohorts: one comprising elderly individuals without chronic kidney disease (CKD) at baseline, and one comprising elderly patients with established CKD.\n\nThe main questions it aims to answer are:\n\nDo metabolic diseases (diabetes, hypertension, hyperlipidemia, hyperuricemia, calcium-phosphorus disorders) increase the risk of incident CKD, major adverse cardiovascular events (MACE), and all-cause mortality in elderly individuals without CKD at baseline? What are the optimal diagnostic thresholds and criteria for CKD in the elderly population? How do metabolic comorbidities affect long-term outcomes - including all-cause mortality, end-stage renal disease (ESRD), and cardiovascular events - in elderly patients with established CKD? What is the comorbidity profile and disease burden of elderly CKD patients in China?\n\nParticipants in both sub-cohorts will:\n\nUndergo baseline assessments including laboratory tests and clinical evaluations.\n\nProvide longitudinal follow-up data through scheduled clinic visits and medical record linkage.\n\nContribute to a large-scale cohort of 100,000 elderly participants across multiple centers in China.",[59,60,61,62,27],"Chronic Kidney Diease","Diabetes Mellitus","Hypertension","Hyperlipidemia",[64,65,66],"chronic kidney disease","elderly","metabolic disorders","NOT_YET_RECRUITING","2026-03-20",{"date":70,"type":39},"2026-03-27",{"date":72,"type":22},"2026-04",{"date":74,"type":22},"2028-12",{"name":76,"class":46},"Chinese PLA General Hospital",2,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100623739","prospective-exploratory-study-on-the-comprehensive-application-effectiveness-of-exercise-prescription-decision-support-tools-in-the-management-of-patients-with-four-highs-hypertension-hyperglycemia-hyperlipidemia-hyperuricemia-100623739","NCT07400549","Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With \"Four Highs\" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)","Inclusion Criteria:\n\n1. Aged 18 years or older.\n2. Willing to participate in the study and able to provide written informed consent.\n3. Diagnosed with at least one of the following \"Four Highs\" conditions:\n\n   Hypertension: Diagnosed primary hypertension, defined as seated office SBP ≥ 140 mmHg and\u002For DBP ≥ 90 mmHg on at least three non-consecutive days, or currently taking antihypertensive medication. Blood pressure must be controlled while on four or more antihypertensive agents. Diabetes Mellitus: Diagnosed diabetes, defined as having typical symptoms plus random plasma glucose ≥ 11.1 mmol\u002FL, or fasting plasma glucose ≥ 7.0 mmol\u002FL, or 2-hour plasma glucose during OGTT\n\n   ≥ 11.1 mmol\u002FL, or HbA1c ≥ 6.5%, or currently taking glucose-lowering medication. HbA1c level must be between 6.5% and 13.0%. Hyperlipidemia: Diagnosed hyperlipidemia, defined as total cholesterol (TC) ≥ 6.22 mmol\u002FL, or LDL-C ≥ 4.14 mmol\u002FL, or HDL-C \\\u003C 1.04 mmol\u002F L, or triglycerides (TG) \\> 2.26 mmol\u002FL, or currently taking lipid-lowering medication. Hyperuricemia: Diagnosed hyperuricemia, defined as a fasting serum uric acid level \\> 420 μmol\u002FL (7 mg\u002FdL) in men and postmenopausal women, or \\> 360 μmol\u002FL (6 mg\u002FdL) in premenopausal women, on two non-consecutive days under a normal purine diet, or currently taking urate-lowering medication.\n4. Capable of using a smartphone.\n5. A local permanent resident who receives basic public health service management at the designated community health center\u002Fstation or township hospital.\n6. Has not engaged in regular moderate- to vigorous-intensity physical activity (defined as at least 30 minutes per session, on at least 3 days per week) in the past three months.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria will be excluded:\n\n1. History or acute episode of cardiovascular or cerebrovascular disease, including: angina pectoris, myocardial infarction, coronary revascularization surgery, stroke (ischemic or hemorrhagic, including transient ischemic attack), symptomatic peripheral arterial disease requiring surgery or diagnosed by vascular imaging, ventricular arrhythmia, uncontrolled atrial fibrillation, congestive heart failure (New York Heart Association Class III or IV), hypertrophic cardiomyopathy, history of aneurysm with diameter ≥ 5.5 cm or prior aneurysm surgery.\n2. Current malignant tumor or history of malignant tumor within the past five years.\n3. Contraindications to exercise, such as bone and joint diseases.\n4. Severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), restricted lung volume (due to obesity, pregnancy, or spinal deformity), or cystic fibrosis.\n5. Neuromuscular and degenerative diseases, such as muscular dystrophy, poliomyelitis, and dementia.\n6. Severe mental illness, including schizophrenia, bipolar disorder, eating disorders, or depression (with hospitalization for the condition within the past 6 months).\n7. Movement and other neurological disorders, such as Huntington's disease, torsion dystonia, Parkinson's disease, and certain epileptic disorders.\n8. Severe comorbidities with a life expectancy of less than 24 months.\n9. Plans to relocate from the area within the next three months.\n10. Participation in other physical activity level intervention programs within the six months prior to the screening visit.\n11. Current participation in another randomized clinical trial.\n12. Any other condition that, in the investigator's judgment, may interfere with adherence to the trial protocol.",{"count":85,"type":22},100,"INTERVENTIONAL",[88],"NA","This study conducted a six-month exploratory clinical trial to evaluate the impact of an exercise prescription mini-program, based on the \"Exercise Guidelines for the 'Four Highs'\", on the physical activity levels and related health indicators of patients with hypertension, hyperglycemia, hyperlipidemia, and hyperuricemia in primary healthcare settings in China.",[61,91,62,27,92],"Hyperglycemia","Digital Intervention",[94,95,96,97],"Digitally-Enabled Health","Chronic Disease Prevention and Control","Sports prescription","Primary health care (PHC)","2026-02-09",{"date":100,"type":39},"2026-02-10",{"date":102,"type":39},"2025-06-01",{"date":104,"type":22},"2026-03-01",{"name":106,"class":107},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":86,"phases":118,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":139},"100539986","phase-1-a-dose-escalation-study-of-ig3018-in-subjects-with-hyperuricemia-with-or-without-chronic-kidney-disease-100539986","NCT06310967","A Dose Escalation Study of IG3018 in Subjects With Hyperuricemia With or Without Chronic Kidney Disease","A Dose Escalation Study of IG3018 to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics in Subjects With Hyperuricemia With or Without Chronic Kidney Disease","Inclusion Criteria:\n\nFor Part 1 and Part 2:\n\nSubjects must meet all the following criteria to be included in the study:\n\n1. Male or female, aged 18 to 75 years (both inclusive).\n2. According to the investigator's judgment, eGFR must be met as:\n\n   Part 1 only: subjects without CKD and have eGFR ≥ 60 mL\u002Fminute\u002F1.73 m2 at screening phase; Part 2 only: subjects with advanced predialysis CKD (Stage 3a, 3b and Stage 4) have eGFR≥15 and \\\u003C60 mL\u002Fminute\u002F1.73 m2 at screening phase.\n3. The serum uric acid level for subjects need to meet any of the following:\n\n   For subjects already on ULT within 2 weeks prior to the screening visit, the serum uric acid would be measured during the screening visit\u002Fphase, and then at the end of the run-in phase, prior to confirming their eligibility. Subjects with ULT within 2 weeks before screening has fasting serum uric acid ≥ 0.48 mmol\u002FL at the end of run-in phase.\n\n   For subjects without ULT in 2 weeks prior to screening visit，the serum uric acid should be measured twice on 2 different days (at least 24 hours apart) prior to confirming their eligibility. Subjects without ULT within 2 weeks before screening has fasting serum uric acid ≥ 0.48 mmol\u002FL at screening phase.\n4. Body Mass Index (BMI) ≥ 18 and ≤ 35 kg\u002Fm2 (both inclusive) at screening.\n5. Female subjects of child-bearing potential \\[defined as women who have experienced menarche but have not reached postmenopausal status (defined as at least 12 consecutive months of amenorrhea without any other identifiable cause other than menopause), and who have not undergone surgery (i.e., bilateral oophorectomy and\u002For bilateral salpingectomy and\u002For hysterectomy) or have no other cause of permanent infertility as determined by the investigator (e.g., Müllerian agenesis).\\] must agree to use highly effective contraceptive methods and must abstain from egg collection or donation from the screening phase to 90 days after the last dose of the IMP. And the male partner of a female subject also needs to agree to use highly effective method of birth control during this phase.\n6. Male subjects considered fertile must agree to not donate sperm, and take effective contraceptive methods from the screening phase to 90 days after the last dose of the IMP. And the female partner of male subjects also needs to agree to use a highly effective method of female contraception during this phase.\n7. Able to understand and give signed written informed consent form (ICF) and willing to comply with all study procedures.\n\n   Only for Part 2\n8. For subjects with anemia who require iron supplementation, steady iron or iron-containing drugs should be used for at least 3 months, and the original treatment regimen should be maintained during the study period.\n\nExclusion Criteria:\n\nFor Part 1 and Part 2:\n\nSubjects who meet any of the following criteria will be excluded from the study:\n\n1. Prior uricase\u002Frecombinant uricase (such as Rasburicase or Pegloticase) therapy within 2 weeks prior to screening or last dose of therapy\\\u003C 5 times the half-life (whichever is longer).\n2. Subjects who have acute gout flares requiring treatment within 4 weeks prior to or during screening.\n3. Major surgery within 3 months prior to the first administration.\n4. History of malignant tumors within 6 months prior to screening.\n5. Subjects within the last 3 months have: myocardial infarction, angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemia attack.\n6. Subjects who are on other urate-lowering medication (allopurinol, febuxostat, probenecid and benzbromarone) and cannot stop during the study periods included in the run-in phase.\n7. Subject with underlying medical conditions requiring changes or introduction of drugs that have the potential impact on the serum uric acid levels (e.g., salicylic acids, diuretics, angiotensin receptor blockers, etc.) within at least 1 month prior the screening phase.\n8. History of gastrointestinal (GI) surgery, including gastric sleeve, colostomy\u002Fenterostomy, Roux-en-Y or gastric banding (unless gastric band removed for a minimum of 12 months prior to screening.\n9. History of GI diseases, including gastrointestinal bleeding moderate to severe gastrointestinal dysfunction, moderate to severe chronic constipation for a minimum of 3 months prior to screening, or newly diagnosed peptic or duodenal ulcer diseases within 4 weeks prior to screening.\n10. Chronic use of parenteral nutrition including manganese within 3 months prior to screening.\n11. Subjects who have the history of manganese toxicity or excessive exposure to manganese (i.e., having worked in a mine, foundry, smelter, dry cell battery manufacturing facility) within 2 months prior to screening.\n12. Inability to swallow oral medications.\n13. Received treatment with or exposure to an investigational drug or device within 30 days of signing informed consent.\n14. Subjects with one of positive results of HIV virus or syphilis, or positive hepatitis B virus surface antigen (HBsAg) and the number of copies of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 500 IU\u002FmL (or 2500 copies, or the lower limit of the positive detection value of the study site) at screening, or HBsAg (-), hepatitis B core antibody (HBcAb) (+) and the number of copies of HBV DNA ≥ 500 IU\u002FmL (or 2500 copies, or the lower limit of the positive detection value of the study site) after treatment of HBV infection, or positive hepatitis C antibody (HCV-Ab), and hepatitis C virus (HCV) ribonucleic acid (RNA) ≥upper limit of normal (ULN) of the study site during screening phase.\n15. History of alcohol abuse, or subjects who consumed alcohol within 48 h before the first administration or did not agree to stop using alcohol products during the study.\n16. Subjects who have previously been diagnosed with the following diseases and have not been able to control them after medication therapy or other treatment. Uncontrolled is defined as hypertension: sSBP ≥ 180 mmHg and\u002For sDBP ≥ 110 mmHg; or Diabetes mellitus: HbA1c ≥ 9% at screening.\n17. Subjects with secondary hyperuricemia caused by tumor, hematological system diseases, drugs, etc. except for chronic kidney disease; or hereditary hyperuricemia at screening.\n18. Subjects undergone kidney transplantation or planning to undergo kidney transplantation at screening.\n19. Subjects with abnormal biliary function, biliary obstruction, or biliary gallstone at screening; Subjects with alanine aminotransferase (ALT) ≥3 ULN, aspartate aminotransferase (AST)≥3 ULN, or total bilirubin (TBIL) ≥1.5 ULN at screening.\n20. Prior or current cholestatic liver disease defined as a clinical condition associated with decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extrahepatic bile ducts.\n21. History of serious hypersensitivity reaction to a known ingredient of IG3018 tablet judged by the investigator.\n22. Subjects who are considered unsuitable for participating in the study in the opinion of the investigator judgment.","75 Years",{"count":117,"type":22},60,[119,120],"PHASE1","PHASE2","This is a phase I\u002FII clinical study to evaluate the safety, tolerability, PK, and efficacy of IG3018 tablet in hyperuricemia (HUA) subjects with or without CKD.",[27,123],"Hypouricemia, Renal",[125,27,126,127,128],"Hyperuricemia, Renal","Chronic Kidney Disease","CKD","Hyperuricemia, CKD","2026-02-01",{"date":131,"type":39},"2026-02-03",{"date":133,"type":39},"2024-11-12",{"date":135,"type":22},"2027-01",{"name":137,"class":138},"Intelligem Therapeutics Australia Pty Ltd.","INDUSTRY",6,{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":16,"sex":17,"minAge":147,"maxAge":115,"enrollmentInfo":148,"targetDuration":4,"studyType":86,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":77},"100582112","phase-1-a-research-study-to-evaluate-the-safety-of-nnc4004-0002-when-given-to-participants-with-asymptomatic-hyperuricemia-100582112","NCT06859073","A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia","A Phase 1, Double-blinded, Placebo-controlled Study of Single Ascending Doses of NNC4004-0002 in Adults With Asymptomatic Hyperuricemia","Inclusion Criteria:\n\n* Males or females 35 to 75 years of age at the time of signing the informed consent form (ICF).\n* Considered to be generally healthy based on medical history, physical examination, and the re-sults of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n* Body mass index (BMI) 20 to 35 kilogram per meter square (kg\u002Fm2) (both inclusive) at screening.\n* Serum uric acid levels greater than or equal to (≥) 6.8 miligram per decileter (mg\u002FdL) to less than or equal (≤) 12 mg\u002FdL on 2 consecutive screening samples (the first at the screening visit \\[V1\\], and the second taken at V2 \\[day -1\\]; samples at least 7 days apart).\n\nExclusion Criteria:\n\n* Female who is pregnant, breastfeeding, or intends to become pregnant or is of childbearing po-tential and not using an adequate contraceptive method.\n* Male of reproductive age who, or whose female partner(s), is not using an adequate contraceptive method.\n* Present or prior history of gout, or present or prior use of serum Uric acid (sUA) lowering medication.\n* Serious cardiovascular or hepatic disease, current or past malignancies, or chronic debilitating neurologic, gastrointestinal, or inflammatory diseases.\n* History or current diagnosis of chronic history kidney disease.\n* Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) values greater than (\\>) 2 multiply by (×) upper limit normal (ULN) or total bilirubin \\>1.5× ULN.","35 Years",{"count":117,"type":22},[119],"This study will evaluate an investigational drug called NNC4004-0002. \"Investigational\" means NNC4004-0002 has not been approved for sale\u002F for clinical use or for the use described in this study\u002F by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.",[152,27],"Healthy Volunteers","2025-09-23",{"date":155,"type":39},"2025-09-24",{"date":157,"type":39},"2024-11-13",{"date":159,"type":22},"2026-06-01",{"name":161,"class":138},"Novo Nordisk A\u002FS",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100605901","is-there-a-relationship-between-uric-acid-level-and-liver-fibrosis-in-obese-patients-100605901","NCT07168551","Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients","Association of Hyperuricemia and Non Alcoholic Fatty Liver Disease and Liver Fibrosis Risk in Adult Obese Patients","Inclusion Criteria:\n\n1. Age: Adults (typically 18-65 years old)\n\n2 - Body Mass Index (BMI): Obese patients with a BMI ≥ 30 kg\u002Fm²\n\n3- Hyperuricemia : Elevated serum uric acid levels (typically \\> 7 mg\u002FdL for men and \\> 6 mg\u002FdL for women)\n\nExclusion Criteria:\n\n* excessive alcohol consumption ( \\> 20 gm \u002Fday in men and 10 in g \u002Fday in women )\n\n  2- use of steatogenic within the past 6 months\n\n  3- positive test for hepatitis B surface antigen and hepatitis B core antibody\n\n  4- Drug induced liver injury and autoimmune hepatitis\n\n  5 - cirrhosis and other causes of liver disease",{"count":170,"type":22},111,"1. Identifying the association between hyperuricemia and NAFLD can lead to early detection and prevention of liver fibrosis in adult obese patients.\n2. Understanding the relationship between hyperuricemia and NAFLD can inform targeted therapy, such as urate-lowering treatment, to potentially slow disease progression.\n\n3 - To examine the relationship between serum uric acid levels and liver fibrosis severity\\*: Assessing the correlation between serum uric acid levels and the severity of liver fibrosis in adult obese patients with NAFLD.\n\n4- To identify potential mechanisms underlying the association\\*: Exploring the potential mechanisms by which hyperuricemia may contribute to the development and progression of NAFLD and liver fibrosis in adult obese patients.",[27,173,174],"NAFLD (Nonalcoholic Fatty Liver Disease)","Liver Fibrosis","2025-09-12",{"date":177,"type":39},"2025-09-15",{"date":179,"type":22},"2025-10-01",{"date":181,"type":22},"2026-12-01",{"name":183,"class":46},"Assiut University",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":202,"locationsCount":47},"100604039","this-study-is-to-estimate-the-efficacy-of-hemodialysis-alone-for-uric-acid-clearance-in-patients-on-hemodialysis-in-order-to-evaluate-the-need-of-adjuvant-uric-acid-lowering-therapy-100604039","NCT07144332","This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Order to Evaluate the Need of Adjuvant Uric Acid Lowering Therapy","Assessment of the Efficacy of Hemodialysis on Uric Acid Clearance at End Stage Kidney Disease in Sohag University Hospital","Inclusion Criteria:\n\n* We included all consenting adults aged 18 or older, on maintenance hemodialysis for at least 3 consecutive months receiving 2 to 3 sessions weekly\n\nExclusion Criteria:\n\n1. Patients aged \\\u003C 18 years old .\n2. Patients on recent hemodialysis less than 3 months.\n3. We excluded patients who were on Uric acid lowering therapy (UALT).\n4. Patients received less than 4 hours of hemodialysis and those who had emergency dialysis.",{"count":85,"type":22},"Background: Uricemia dramatically rises with the stage of chronic kidney disease (CKD) and correlates with its mortality. Hemodialysis (HD) being the most used treatment at the end stage kidney disease in Sohag governorate , we sought to evaluate its efficacy on the clearance of uric acid (UAc) when used alone and twice per week.\n\nMethods: A cross-sectional study of all consenting patients with CKD stage 5 recruited at random during hemodialysis sessions at hemodialysis unit in Sohag university hospital from July to December 2025. We collected socio-demographic data, relevant clinical information, hemodialysis related variables, and measured serum uric acid (SUA) levels before and after the dialysis to assess the uric acid clearance. A clearance between 65 and 80% and above 80% was considered as low and good efficacy of hemodialysis respectively",[194,27],"Hemodialysis",[194,27,64],"2025-08-20",{"date":198,"type":39},"2025-08-27",{"date":200,"type":39},"2025-07-13",{"date":129,"type":22},{"name":203,"class":46},"Sohag University",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":214,"conditions":215,"keywords":216,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":47},"100591533","effects-of-fibres-combined-with-probiotics-on-uric-acid-in-an-ex-vivo-fermentation-model-100591533","NCT06981663","Effects of Fibres Combined With Probiotics on Uric Acid in an ex Vivo Fermentation Model","Potential Effects of Fibres Combined With Probiotics on Uric Acid and Related Metabolites in an ex Vivo Fermentation Model","Inclusion Criteria:\n\n1. Signed informed consent prior to any study-related procedures\n2. Age 18-80 years old\n3. BMI range 18.5-35 kg\u002Fm2\n4. Blood uric acid above 0.36 mmol\u002FL (6 mg\u002Fdl)\n5. Willing to abstain from regular consumption of probiotic supplements or food products containing probiotic bacteria (including fermented food and beverages), until collection of faecal material\n6. Willing to abstain from regular consumption of supplements and medications known to alter gastrointestinal function or inflammatory status during the study, until collection of faecal material\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 and\u002For type 2 diabetes\n2. Diagnosed inflammatory bowel disease (IBD)\n3. Current diagnosis of psychiatric disease\u002Fs or syndromes\n4. Current diagnosis of neurodegenerative disease\n5. Current pregnancy or breastfeeding\n6. History of complicated gastrointestinal surgery\n7. Systemic use of antibiotics and\u002For steroid medication in the last 4 months prior to inclusion\n8. Regular use of any non-steroidal anti-inflammatory drug (NSAID) for the last 2 months\n9. Consumption of any NSAID within 3 days of sample collection\n10. Current (or within the last 4 weeks prior to study start) use of probiotic supplementation\n11. Any condition or intake of medication which could substantially interfere with the outcome of the study, as decided by the principal investigator's discretion\n12. After being included in the study and until collection of faecal material, starting any medication or treatment that could potentially influence the study participation and\u002For study analysis","80 Years",{"count":213,"type":22},15,"In this study, we will collect faecal samples from individuals with hyperuricaemia (assessed by blood test) and perform in vitro faecal fermentation studies to assess how probiotics in combination with fibres affect urate metabolism in these faecal samples.",[27],[31],"2025-08-11",{"date":219,"type":39},"2025-08-12",{"date":221,"type":39},"2025-06-12",{"date":74,"type":22},{"name":224,"class":46},"Örebro University, Sweden",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":232,"targetDuration":4,"studyType":86,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":47},"100564453","phase-1-safety-tolerability-and-pharmacokinetic-characteristics-of-sss11-in-patients-with-gout-and-hyperuricemia-100564453","NCT06629376","Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia","Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacological Studies of SSS11 in Patients With Gout and Hyperuricemia After Multiple Administrations, Dose Escalation, Randomized Double-blind, Placebo-controlled Trials","Inclusion Criteria:\n\n* A patient with clinical diagnosis of gout (according to the 2015 ACR\u002FEULAR gout classification criteria), non acute attack phase, and hyperuricemia {under normal purine diet, blood uric acid\\>420 µ mol\u002FL (7 mg\u002Fdl) not tested twice on an empty stomach on the same day}。\n* Screening period blood uric acid\\>420 µ mol\u002FL (7mg\u002Fdl)。\n\nExclusion Criteria:\n\n* Within 14 days prior to enrollment (or within 5 half lives of the drug, whichever is longer), medication that lowers uric acid levels or affects uric acid levels and related drugs (allopurinol, febuxostat, benzbromarone, probenecid, benzenesulfonazolone, Tongyifengning tablets, etc.) must be taken, or during the study period, other drugs that lower uric acid levels or affect uric acid levels and related drugs other than experimental drugs must not be discontinued。\n* Patients with acute gout attacks within 14 days prior to enrollment。\n* Previously received uric acid oxidase or treated with similar drugs such as pegolase or rabulidase。\n* Individuals with a history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD enzyme activity levels below the lower limit of normal。\n* Individuals with a history of catalase deficiency or evidence that meets the diagnostic criteria for catalase deficiency。\n* Malignant tumor patients (whether treated or not)。",{"count":117,"type":22},[119],"This is a safety, tolerability, pharmacokinetics, and preliminary pharmacological study of multiple administration, dose escalation, randomized double-blind, placebo-controlled.The main purpose of this experiment is to evaluate the safety and tolerability of multiple injections of PEGylated recombinant Candida urate oxidase (test drug code: SSS11) in patients with gout and hyperuricemia.The experimental period includes a screening period of 4 weeks, a treatment period of 4 or 8 weeks, and an observation period of 4 weeks。",[236,27],"Gout","2025-05-26",{"date":239,"type":39},"2025-05-28",{"date":241,"type":39},"2023-11-20",{"date":243,"type":22},"2027-08-08",{"name":245,"class":138},"Shenyang Sunshine Pharmaceutical Co., LTD.",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":252,"targetDuration":254,"studyType":23,"phases":4,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100561136","screening-and-management-of-hyperuricemia-in-patients-with-chronic-medical-diseases-in-assiut-university-hospital-100561136","NCT06586229","Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospital","Inclusion Criteria:\n\n* Patients 18 years of age or older who were diagnosed with chronic medical diseases as diabetes mellitus , hypertension , obesity , metabolic syndrome , chronic kidney disease and cardiovascular disease (ischemic cardiomyopathy, heart failure ,coronary arteries disease) .\n\nExclusion Criteria:\n\n* patients under the age of 18.\n* patients kown to have gouty arthritis\n* patients with acute kidney disease .\n* patients receiving thiazide diuretics.\n* patients with tumour lysis syndrome .",{"count":253,"type":22},61,"1 Year","In this study, we aimed to evaluate patients with chronic medical diseases in Assiut university hospitals for -Detection of asymptomatic hyperuricemia .\n\n* Early identification of associated comorbidities .\n* Management of indicated hyperurecimia .",[27],"2024-09-16",{"date":259,"type":39},"2024-09-19",{"date":261,"type":22},"2024-10-01",{"date":263,"type":22},"2025-11-01",{"name":183,"class":46},{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":211,"enrollmentInfo":273,"targetDuration":4,"studyType":86,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":47},"100551705","phase-4-cpap-effect-on-lipid-profile-and-hyperuricemia-in-patients-with-dyslipidemia-and-moderate-severe-obstructive-sleep-apnea-100551705","NCT06463561","CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea","Effect of 12 Months of Treatment With Continuous Positive Airway Pressure on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea. A Randomized, Open-labell, Parallel Clinical Trial","CPAPLIP","Inclusion Criteria:\n\n* Subjects from 35 to 80 years old\n* Diagnosis of dyslipidemia. It will be considered as such, the existence of a previous clinical record of a diagnosis of dyslipidemia associated with treatment with lipidlowering agents, treatment with lipid-lowering agents or the presence of an altered blood test in the last two months, using the following cut-off points: total cholesterol ≥ 200 mg\u002Fdl, triglycerides ≥ 180 mg\u002Fdl, HDL-cholesterol ≤ 40 mg\u002Fdl or LDL-cholesterol ≥ 150 mg\u002Fdl.\n* Moderate-severe sleep apnea, defined by AHI \\> 15 h-1 .\n\nExclusion Criteria:\n\n* Predominance of central apneas-hypopneas, defined as more than 25% of total respiratory events.\n* Patients with indications for CPAP treatment according to the International Sleep Consensus: hypertensive, excessive daytime sleepiness (Epworth Sleepiness Scale \\> 11) or impaired sleep-related quality of life considered relevant by their regular physician.\n* Professional drivers, at-risk profession or respiratory insufficiency (according to criteria of the clinical pathway for the diagnosis and treatment of sleep-disordered breathing).\n* Pretreatment with CPAP",{"count":274,"type":22},220,[276],"PHASE4","Clinical Trial Phase IV Indication: Moderate-severe obstructive sleep apnea and dyslipidemia.\n\nObjectives:\n\nMain objective: To test whether 12 months of CPAP treatment associated with conventional pharmacological treatment improves the lipid profile of patients with dyslipidemia and moderate to severe OSA.\n\nSecondary objectives:\n\n* To test whether 12 months of treatment with CPAP associated with conventional pharmacological treatment improves serum uric acid concentration in patients with dyslipidemia and moderate-severe OSA.\n* To determine the additional medium- and long-term effect of CPAP on insulin resistance in patients with dyslipidemia and moderate-severe OSA.\n* To evaluate the impact of CPAP treatment on cardiovascular risk reduction in patients with dyslipidemia and moderate-severe OSA.\n* To analyze the impact of supplemental CPAP treatment on glycemic control and C-reactive protein concentration in patients with dyslipidemia and moderate-severe OSA.\n* To establish the impact of supplemental CPAP therapy on health-related quality of life in patients with dyslipidemia and moderate-severe OSA.\n* To evaluate the effect of CPAP on inflammatory cytokines, oxidative stress biomarkers, sympathetic tone and intake-regulating hormones in patients with dyslipidemia and moderate-severe OSA.\n* To relate CPAP-induced changes in serum lipid and uric acid concentration to changes in basal inflammatory response, oxidative stress, sympathetic activity, and intake-regulating hormones.\n* To identify the subgroup of patients with dyslipidemia and moderate-severe OSA in whom 12 months of CPAP treatment achieves a more marked reduction in serum lipids and uric acid.\n\nDesign Randomized, parallel-group, nonblinded, controlled clinical trial with conventional treatment.\n\nStudy population Subjects aged 35 to 80 years with a diagnosis of dyslipidemia made at least six months ago and with moderate-severe obstructive sleep apnea (OSA) not requiring CPAP treatment according to conventional indications.\n\nSample size: 110 patients in each treatment arm.\n\nTreatment Patients will be randomly assigned in a 1:1 ratio to one of the following treatment arms:\n\n1. Conventional hygienic-dietary recommendations and promotion of daily physical activity.\n2. Conventional hygienic-dietary recommendations and promotion of daily physical activity, plus treatment with positive airway pressure (CPAP).\n\nEfficiency variables\n\n* Main variables: LDL-cholesterol and uric acid.\n* Total cholesterol, HDL-cholesterol and triglycerides.\n* Basal blood glucose, glycosylated hemoglobin (HbA1c), creatinine and C-reactive protein.\n* Systemic biomarkers: inflammatory (IL-6, IL-8 and TNF-α), oxidative stress (8-isoprostane), endothelial damage (endothelin, VCAM-1 and ICAM-1), sympathetic activity (neuropeptide Y) and appetite-regulating hormones (leptin, orexin A\u002Fhypocretin 1 and ghrelin).\n* Clinical questionnaires: SF-12, EuroQoL, FOSQ and IPAQ.\n\nSafety variables\n\n* Clinical adverse event reporting.\n* CPAP compliance (average hours of use per day).\n* Epworth Sleepiness Questionnaire.\n* Development of cardiovascular events.",[279,280,27],"Sleep Apnea","Dyslipidemias","2024-07-11",{"date":283,"type":39},"2024-07-15",{"date":285,"type":39},"2024-07-12",{"date":287,"type":22},"2028-01-31",{"name":289,"class":46},"Hospital Universitario La Paz",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":298,"conditions":299,"keywords":302,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":47},"100475876","risk-factors-and-multiomics-study-of-chronic-kidney-disease-caused-by-metabolic-diseases-100475876","NCT05476627","Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases","Inclusion Criteria:\n\n* The diagnosis of metabolic diseases were confirmed;\n* Be able to understand the process of the research;\n* Volunteer for participation and be able to sign the informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C18 yrs or \\>80yrs;\n* Patients with primary and secondary glomerular diseases\n* Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and\u002For renal tumors;\n* Contraindications for MRI examination;\n* Pregnant or lactation patients;\n* Patients with unstable vital signs, failure of other organs or dysphoria.",{"count":297,"type":22},200,"With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.",[300,61,60,27,301],"Chronic Kidney Diseases","Obesity",[64,303,304,305],"metabolic diseases","biomarker","functional imaging techniques","2022-08-12",{"date":308,"type":39},"2022-08-16",{"date":310,"type":39},"2022-07-01",{"date":312,"type":22},"2027-07-01",{"name":314,"class":46},"Peking Union Medical College Hospital"]